{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:36:23Z","timestamp":1762522583400,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment options for metastatic breast cancer (MBC) refractory to anthracyclines and taxanes are limited. In a phase III trial, eribulin demonstrated a significant improvement in overall survival compared to treatment of physician\u2019s choice, but had limited tolerability because of neutropenia and peripheral neuropathy. Based on prior studies of alternative treatment schedules with other therapies, we hypothesized that a low-dose metronomic schedule of eribulin would permit patients to remain on treatment more consistently without treatment delays, resulting in longer time to progression, and improved toxicity profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a multi-site single arm, phase II trial patients with MBC. All patients were treated with metronomic eribulin (0.9\u00a0mg\/m<jats:sup>2<\/jats:sup> administered intravenously on days 1, 8, and 15 of a 28-day cycle.) Treatment was continued until the patient developed disease progression, unacceptable toxicity, or chose to stop the study. Patients must have had prior taxane exposure. The primary endpoint was progression-free survival. Secondary end points were overall survival, response rate, and clinical benefit rate. Exploratory biomarkers were performed to analyze change in levels of circulating endothelial cells (CECs), circulating endothelial precursors, and carbonic anhydrase IX (CAIX) with response to therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>We consented 86 patients and 59 were evaluable for final analysis. Median age was 59\u00a0years; 78% had HER2 negative tumors. The median progression-free survival (PFS) was 3.5\u00a0months with overall survival (OS) of 14.3\u00a0months. Objective response rate was 15% with clinical benefit rate of 48%. Reported grade 3 neutropenia and peripheral neuropathy were 18% and 5%, respectively. Treatment discontinuation due to toxicity was seen in 3% of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretation<\/jats:title>\n                <jats:p>Metronomic weekly low-dose eribulin is an active and tolerable regimen with significantly less myelosuppression, alopecia, and peripheral neuropathy than is seen with the approved dose and schedule, allowing longer duration of use and disease control, with similar outcomes compared to the standard dose regimen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-021-06175-x","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T07:02:26Z","timestamp":1617346946000},"page":"91-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer"],"prefix":"10.1007","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-2979","authenticated-orcid":false,"given":"Pavani","family":"Chalasani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiah","family":"Farr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayakrishna K.","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Specht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"issue":"1","key":"6175_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"6175_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000477404","volume":"93","author":"P Chalasani","year":"2017","unstructured":"Chalasani P (2017) Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations. Oncology 93(3):143\u2013156. https:\/\/doi.org\/10.1159\/000477404","journal-title":"Oncology"},{"unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_blocks.pdf. Accessed 10 Jan 2021","key":"6175_CR3"},{"issue":"9769","key":"6175_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) EMBRACE (Eisai metastatic breast cancer study assessing physician\u2019s choice versus E7389) investigators. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"key":"6175_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1078155214525369","volume":"21","author":"G Dranitsaris","year":"2015","unstructured":"Dranitsaris G, Beegle N, Kalberer T et al (2015) A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Pharm Pract 21:170\u2013177","journal-title":"J Oncol Pharm Pract"},{"key":"6175_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40064-016-1700-0","volume":"5","author":"O Garrone","year":"2016","unstructured":"Garrone O, Montemurro F, Saggia C et al (2016) Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial\u2014a multicenter retrospective study of eribulin in real life. Springerplus 5:59","journal-title":"Springerplus"},{"key":"6175_CR7","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1002\/cam4.1705","volume":"7","author":"SS Mougalian","year":"2018","unstructured":"Mougalian SS, Copher R, Kish JK et al (2018) Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: long-term outcomes of patients treated in the US community oncology setting. Cancer Med 7:4371\u20134378","journal-title":"Cancer Med"},{"key":"6175_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2016.03.010","volume":"60","author":"P Aftimos","year":"2016","unstructured":"Aftimos P, Polastro L, Ameye L et al (2016) Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. Eur J Cancer 60:117\u2013124","journal-title":"Eur J Cancer"},{"issue":"5","key":"6175_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14740338.2019.1608946","volume":"18","author":"JM Perez-Garcia","year":"2019","unstructured":"Perez-Garcia JM, Cortes J (2019) The safety of eribulin for the treatment of metastatic breast cancer. Expert Opin Drug Saf 18(5):347\u2013355","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"6175_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8):1045\u20131047","journal-title":"J Clin Invest"},{"issue":"34","key":"6175_CR11","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","volume":"29","author":"MR Stockler","year":"2011","unstructured":"Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK et al (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498\u20134504","journal-title":"J Clin Oncol"},{"issue":"2","key":"6175_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","volume":"108","author":"Mancuso","year":"2006","unstructured":"Mancuso et al (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2):452\u2013459","journal-title":"Blood"},{"issue":"5","key":"6175_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10428190902856808","volume":"50","author":"AT Stopeck","year":"2009","unstructured":"Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP (2009) A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma 50(5):728\u2013735. https:\/\/doi.org\/10.1080\/10428190902856808","journal-title":"Leuk Lymphoma"},{"key":"6175_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","volume":"26","author":"JL Glade Bender","year":"2008","unstructured":"Glade Bender JL, Adamson PC, Reid JM et al (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children\u2019s oncology group study. J Clin Oncol 26:399\u2013405","journal-title":"J Clin Oncol"},{"key":"6175_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9810383","volume":"2016","author":"U Brown-Glaberman","year":"2016","unstructured":"Brown-Glaberman U, Marron M, Chalasani P, Livingston R, Iannone M, Specht J, Stopeck AT (2016) Circulating carbonic anhydrase IX and antiangiogenic therapy in breast cancer. Dis Mark 2016:1. https:\/\/doi.org\/10.1155\/2016\/9810383","journal-title":"Dis Mark"},{"issue":"3","key":"6175_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Shaked","year":"2008","unstructured":"Shaked et al (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14(3):263\u2013273","journal-title":"Cancer Cell"},{"issue":"5974","key":"6175_CR17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1126\/science.1127592","volume":"313","author":"Shaked","year":"2006","unstructured":"Shaked et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5974):1785\u20131787","journal-title":"Science"},{"issue":"19","key":"6175_CR18","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1158\/0008-5472.CAN-09-0381","volume":"69","author":"Shaked","year":"2009","unstructured":"Shaked et al (2009) Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69(19):7524\u20137528","journal-title":"Cancer Res"},{"issue":"1","key":"6175_CR19","first-page":"27","volume":"1796","author":"Bertolini","year":"2009","unstructured":"Bertolini et al (2009) The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochem Biophys Acta 1796(1):27\u201332","journal-title":"Biochem Biophys Acta"},{"issue":"7","key":"6175_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cam4.447","volume":"4","author":"P Chalasani","year":"2015","unstructured":"Chalasani P, Marron M, Roe D, Clarke K, Iannone M, Livingston RB, Shan JS, Stopeck AT (2015) A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med 4(7):1051\u20131059. https:\/\/doi.org\/10.1002\/cam4.447","journal-title":"Cancer Med"},{"issue":"2","key":"6175_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clbc.2019.09.007","volume":"20","author":"J Smith 2nd","year":"2020","unstructured":"Smith J 2nd, Irwin A, Jensen L, Tedesco K, Misir S, Zhu W, Almonte A, He Y, Xie R, Olivo M, O\u2019Shaughnessy J (2020) Phase II study or eribulin mesylate administered biweekly in patients with human epidermal growth factor receptor-2 negative metastatic breast cancer. Clin Breast Cancer 20(2):160\u2013167","journal-title":"Clin Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06175-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06175-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06175-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T15:32:17Z","timestamp":1624635137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06175-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6175"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06175-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for all subjects enrolled in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}